MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology (Laboratory Equipment, Testing, Tools, Reagents & Test Kit Companies)
Exact Sciences Corporation (NASDAQ:EXAS)*
Organization & Developments: Exact Sciences
Parents
Exact Sciences Corporation (NASDAQ:EXAS)*
Children
*Early clinical testing has shown Exact’s test to be far more sensitive and specific than the existing screening standard.
*Exact Sciences is a molecular diagnostics company focused on colorectal cancer.
*Genomic-based screening test for colorectal cancer.
*Stool-based DNA (sDNA) technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.
*The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer.
2014 Medtech Company of the Year Finalists: Exact Sciences
2014: Exact Sciences expects a final payment decision from CMS in October or November, 2014 Medtech Company of the Year Finalists: Exact Sciences
2014: Exact Sciences hopes the test will also be included in colorectal cancer screening guidelines issued by organizations such as the American Cancer Society by the end of 2015.
2014: In August, Exact Sciences was granted PMA approval for Cologard, the first and only FDA-approved DNA test for colorectal cancer.
2014: Non-Invasive Colon Cancer Screening: Interview with Exact Sciences CEO Kevin Conroy
2016: Exact Sciences’ Cologuard Wins Prestigious Prix Galien Award for Best Medical Technology Product
2018: EXACT Sciences Corp.: We Admit To Being Early; But The Science Won't Be Held Back - EXACT Sciences Corporation (NASDAQ:EXAS)
2018: Exact Sciences Shares Rise After Company Unveils Pfizer Partnership
2019: Doubt cast on value of Exact Sciences' Cologuard
2019: FDA Decision Expands Market for Exact Sciences’ Cologuard Test
2020: Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test
2020: Exact Sciences' Grand Endeavor
2022 Exact Sciences Corporation 2022 Q3 - Results - Earnings Call Presentation_seekingalpha.com
2022: Exact Sciences Q3 Earnings: Profitability Goal Execution Momentum Building Into 2023_seekingalpha.com
2022: Exact Sciences: Price Is Yet To Catch Up As Management Draws On Profitability Plans_seekingalpha.com
2022: Exact Sciences: Sell-Off Provides An Opportunity To Buy At A Reasonable Valuation
2023: Exact Sciences Up 25% YTD: Here Is What To Expect In 2023_ seekingalpha.com
2023: Exact Sciences: Defending ARK's Call Of $140 Per Share By 2027_ seekingalpha.com
2024: Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight
2024: Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight
2024: Exact Sciences Corporation 2023 Q4 - Results - Earnings Call Presentation
2024: Exact Sciences wins FDA approval for Cologuard Plus colorectal cancer test
2024: Exact Sciences: Cancer Battle Continues, Shares Likely To Plateau
2024: Exact Sciences: Cancer Detection Stalwart's Bad Quarter Resets Its Overgrown Market Cap.
2024: Exact Sciences: Profitability Remains Elusive_ seekingalpha.com
2024: Exact Sciences: Q3 Sell-Off May Be Unjustified, But Long-Term Outlook A Concern
2025: Exact Sciences rolls out Cancerguard multi-cancer blood test
2025: Exact Sciences: Liquid Biopsy Threat Is Solidifying
2025: Fifty cancer types in one liquid biopsy test: Exact Sciences enters early-detection market
2025:Only 4 cancers are routinely screened. From promise to practice: MCED adoption accelerates despite operational hurdle
2026: Multi-Cancer Early Detection Goes Global and Gets Personal
Jumps
*Key People: Exact Sciences
Finance & Acquisitions: Exact Sciences